Skip to main content
Erschienen in: Journal of Cancer Research and Clinical Oncology 5/2020

24.02.2020 | Original Article – Clinical Oncology

Stereotactic body radiotherapy for elderly patients (≥ 75 years) with early-stage non-small cell lung cancer

verfasst von: Zekai Shu, Baiqiang Dong, Lei Shi, Wei Shen, Qingqing Hang, Jin Wang, Yuanyuan Chen

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 5/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Stereotactic body radiotherapy (SBRT) is the primary treatment method for early-stage non-small cell lung cancer (NSCLC) considered inoperable due to medical comorbidities. However, the application of SBRT in patients aged ≥ 75 years has not been adequately studied. This retrospective study aimed to investigate the effectiveness and safety of SBRT in early-stage NSCLC patients aged ≥ 75 years, and the impact of treatment on nutritional status and self-care ability.

Methods

Histopathologically confirmed early-stage (T1-3N0M0) NSCLC patients aged ≥ 75 years treated with SBRT between 2013 and 2018 at our center were identified from the electronic database. Treatment efficacy, treatment toxicities, impact of treatment on nutritional status, and self-care ability were retrospectively analyzed. Toxicities were evaluated according to the Common Terminology Criteria for Adverse Event (CTCAE) (Common 2010) version 4.0. Nutritional status was assessed by Nutritional Risk Screening 2002 criteria, and self-care ability by Barthel index and fall risk index.

Results

A total of 68 patients were enrolled. Median follow-up duration was 46.3 (3.9–80.1) months. The 1-, 3-, and 5-year overall survival rates were 92.6%, 77.2%, and 59.1%, respectively, and the 1-year, 3-year and 5-year local control rates were 95.6%, 88.9% and 85.6%, respectively. Grade 1–2 and grade 3 radiation pneumonitis occurred in 60/68 (96.8%) and 1/68 (1.5%) patients, respectively. Fall risk at 3 months after treatment was not significantly different from that before treatment (P = 0.22). Barthel index increased significantly after treatment (P < 0.001).

Conclusions

SBRT appears to be effective and safe for NSCLC patients aged ≥ 75 years, with no adverse impact on nutritional status and self-care ability.
Literatur
Zurück zum Zitat Detillon D, Driessen EJM, Aarts MJ, Janssen-Heijnen MLG, van Eijck CHJ, Veen EJ (2018) Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery. Eur J Cancer (Oxford England: 1990) 101:30–37. https://doi.org/10.1016/j.ejca.2018.06.016CrossRef Detillon D, Driessen EJM, Aarts MJ, Janssen-Heijnen MLG, van Eijck CHJ, Veen EJ (2018) Changes in treatment patterns and survival in elderly patients with stage I non-small-cell lung cancer with the introduction of stereotactic body radiotherapy and video-assisted thoracic surgery. Eur J Cancer (Oxford England: 1990) 101:30–37. https://​doi.​org/​10.​1016/​j.​ejca.​2018.​06.​016CrossRef
Zurück zum Zitat Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990) 45:228–247. 10.1016/j.ejca.2008.10.026 Eisenhauer EA et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer (Oxford, England: 1990) 45:228–247. 10.1016/j.ejca.2008.10.026
Zurück zum Zitat Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, Senan S (2009) Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol (London, England) 4:1. https://doi.org/10.1186/1748-717x-4-1CrossRef Hurkmans CW, Cuijpers JP, Lagerwaard FJ, Widder J, van der Heide UA, Schuring D, Senan S (2009) Recommendations for implementing stereotactic radiotherapy in peripheral stage IA non-small cell lung cancer: report from the Quality Assurance Working Party of the randomised phase III ROSEL study. Radiat Oncol (London, England) 4:1. https://​doi.​org/​10.​1186/​1748-717x-4-1CrossRef
Zurück zum Zitat Kondrup J, Allison SP, Elia M, Vellas B, Plauth M (2003) ESPEN guidelines for nutrition screening 2002. Clin Nutr (Edinburgh, Scotland) 22:415–421CrossRef Kondrup J, Allison SP, Elia M, Vellas B, Plauth M (2003) ESPEN guidelines for nutrition screening 2002. Clin Nutr (Edinburgh, Scotland) 22:415–421CrossRef
Zurück zum Zitat Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. Md State Med J 14:61–65PubMed Mahoney FI, Barthel DW (1965) Functional evaluation: the Barthel Index. Md State Med J 14:61–65PubMed
Zurück zum Zitat Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A (2016) Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ (Clinical research ed) 354:i3570. https://doi.org/10.1136/bmj.i3570CrossRef Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A (2016) Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ (Clinical research ed) 354:i3570. https://​doi.​org/​10.​1136/​bmj.​i3570CrossRef
Zurück zum Zitat Wu G, Gu X, Yuan D, Yao Y, Yang W, Lv T, Song Y (2019) Diagnosis status and pathological diagnosis derived treatment of elderly lung cancer patients over 75 years old. Transl Cancer Res 8:87–95. 10.21037/tcr.2018.12.35. Wu G, Gu X, Yuan D, Yao Y, Yang W, Lv T, Song Y (2019) Diagnosis status and pathological diagnosis derived treatment of elderly lung cancer patients over 75 years old. Transl Cancer Res 8:87–95. 10.21037/tcr.2018.12.35.
Metadaten
Titel
Stereotactic body radiotherapy for elderly patients (≥ 75 years) with early-stage non-small cell lung cancer
verfasst von
Zekai Shu
Baiqiang Dong
Lei Shi
Wei Shen
Qingqing Hang
Jin Wang
Yuanyuan Chen
Publikationsdatum
24.02.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Cancer Research and Clinical Oncology / Ausgabe 5/2020
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-020-03154-5

Weitere Artikel der Ausgabe 5/2020

Journal of Cancer Research and Clinical Oncology 5/2020 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.